nodes	percent_of_prediction	percent_of_DWPC	metapath
Minocycline—VEGFA—uterine cancer	0.67	1	CbGaD
Minocycline—CYCS—exocrine gland—uterine cancer	0.00578	0.0404	CbGeAlD
Minocycline—CASP3—artery—uterine cancer	0.00568	0.0397	CbGeAlD
Minocycline—CASP3—exocrine gland—uterine cancer	0.00495	0.0346	CbGeAlD
Minocycline—IL1B—artery—uterine cancer	0.00454	0.0317	CbGeAlD
Minocycline—MMP9—artery—uterine cancer	0.00378	0.0264	CbGeAlD
Minocycline—CASP1—myometrium—uterine cancer	0.00333	0.0232	CbGeAlD
Minocycline—IL1B—Methylprednisolone—Medroxyprogesterone Acetate—uterine cancer	0.00307	0.577	CbGdCrCtD
Minocycline—CASP3—myometrium—uterine cancer	0.00275	0.0192	CbGeAlD
Minocycline—CASP1—epithelium—uterine cancer	0.00261	0.0182	CbGeAlD
Minocycline—CASP1—uterine cervix—uterine cancer	0.00259	0.0181	CbGeAlD
Minocycline—CYCS—epithelium—uterine cancer	0.00252	0.0176	CbGeAlD
Minocycline—CYCS—uterine cervix—uterine cancer	0.00249	0.0174	CbGeAlD
Minocycline—CASP1—decidua—uterine cancer	0.00247	0.0172	CbGeAlD
Minocycline—CASP1—renal system—uterine cancer	0.00242	0.0169	CbGeAlD
Minocycline—CYCS—smooth muscle tissue—uterine cancer	0.00242	0.0169	CbGeAlD
Minocycline—CASP1—endometrium—uterine cancer	0.00234	0.0164	CbGeAlD
Minocycline—CYCS—renal system—uterine cancer	0.00233	0.0163	CbGeAlD
Minocycline—CASP1—mammalian vulva—uterine cancer	0.00227	0.0158	CbGeAlD
Minocycline—IL1B—myometrium—uterine cancer	0.00219	0.0153	CbGeAlD
Minocycline—CASP1—uterus—uterine cancer	0.00216	0.0151	CbGeAlD
Minocycline—VEGFA—myometrium—uterine cancer	0.00216	0.0151	CbGeAlD
Minocycline—CASP3—epithelium—uterine cancer	0.00215	0.015	CbGeAlD
Minocycline—CASP3—uterine cervix—uterine cancer	0.00214	0.0149	CbGeAlD
Minocycline—CYCS—uterus—uterine cancer	0.00208	0.0145	CbGeAlD
Minocycline—CASP3—smooth muscle tissue—uterine cancer	0.00208	0.0145	CbGeAlD
Minocycline—CASP3—decidua—uterine cancer	0.00204	0.0142	CbGeAlD
Minocycline—CASP3—renal system—uterine cancer	0.002	0.0139	CbGeAlD
Minocycline—CASP1—female reproductive system—uterine cancer	0.00194	0.0135	CbGeAlD
Minocycline—CASP3—endometrium—uterine cancer	0.00193	0.0135	CbGeAlD
Minocycline—IL1B—Fluorometholone—Medroxyprogesterone Acetate—uterine cancer	0.0019	0.358	CbGdCrCtD
Minocycline—CASP3—mammalian vulva—uterine cancer	0.00187	0.013	CbGeAlD
Minocycline—CYCS—female reproductive system—uterine cancer	0.00187	0.013	CbGeAlD
Minocycline—CASP3—uterus—uterine cancer	0.00178	0.0124	CbGeAlD
Minocycline—CASP1—female gonad—uterine cancer	0.00177	0.0123	CbGeAlD
Minocycline—CASP1—vagina—uterine cancer	0.00176	0.0123	CbGeAlD
Minocycline—IL1B—epithelium—uterine cancer	0.00172	0.012	CbGeAlD
Minocycline—CYCS—female gonad—uterine cancer	0.0017	0.0119	CbGeAlD
Minocycline—VEGFA—uterine cervix—uterine cancer	0.00168	0.0117	CbGeAlD
Minocycline—IL1B—smooth muscle tissue—uterine cancer	0.00166	0.0116	CbGeAlD
Minocycline—VEGFA—smooth muscle tissue—uterine cancer	0.00163	0.0114	CbGeAlD
Minocycline—IL1B—decidua—uterine cancer	0.00163	0.0113	CbGeAlD
Minocycline—CASP3—female reproductive system—uterine cancer	0.0016	0.0112	CbGeAlD
Minocycline—VEGFA—decidua—uterine cancer	0.0016	0.0112	CbGeAlD
Minocycline—IL1B—renal system—uterine cancer	0.0016	0.0111	CbGeAlD
Minocycline—IL1B—endometrium—uterine cancer	0.00154	0.0108	CbGeAlD
Minocycline—VEGFA—endometrium—uterine cancer	0.00152	0.0106	CbGeAlD
Minocycline—VEGFA—mammalian vulva—uterine cancer	0.00147	0.0102	CbGeAlD
Minocycline—CASP3—female gonad—uterine cancer	0.00146	0.0102	CbGeAlD
Minocycline—CASP3—vagina—uterine cancer	0.00145	0.0101	CbGeAlD
Minocycline—MMP9—epithelium—uterine cancer	0.00143	0.01	CbGeAlD
Minocycline—IL1B—uterus—uterine cancer	0.00142	0.00993	CbGeAlD
Minocycline—MMP9—uterine cervix—uterine cancer	0.00142	0.00993	CbGeAlD
Minocycline—VEGFA—uterus—uterine cancer	0.0014	0.00976	CbGeAlD
Minocycline—MMP9—smooth muscle tissue—uterine cancer	0.00138	0.00965	CbGeAlD
Minocycline—MMP9—decidua—uterine cancer	0.00136	0.00946	CbGeAlD
Minocycline—MMP9—renal system—uterine cancer	0.00133	0.00929	CbGeAlD
Minocycline—MMP9—endometrium—uterine cancer	0.00129	0.00898	CbGeAlD
Minocycline—IL1B—female reproductive system—uterine cancer	0.00128	0.00892	CbGeAlD
Minocycline—SLC22A11—renal system—uterine cancer	0.00126	0.0088	CbGeAlD
Minocycline—SLC22A7—renal system—uterine cancer	0.00123	0.00859	CbGeAlD
Minocycline—MMP9—uterus—uterine cancer	0.00119	0.00827	CbGeAlD
Minocycline—IL1B—female gonad—uterine cancer	0.00116	0.00812	CbGeAlD
Minocycline—IL1B—vagina—uterine cancer	0.00116	0.00807	CbGeAlD
Minocycline—VEGFA—female gonad—uterine cancer	0.00114	0.00799	CbGeAlD
Minocycline—VEGFA—vagina—uterine cancer	0.00114	0.00794	CbGeAlD
Minocycline—CASP1—lymph node—uterine cancer	0.00114	0.00793	CbGeAlD
Minocycline—CYCS—lymph node—uterine cancer	0.00109	0.00763	CbGeAlD
Minocycline—ALOX5—smooth muscle tissue—uterine cancer	0.00109	0.00763	CbGeAlD
Minocycline—ALOX5—decidua—uterine cancer	0.00107	0.00748	CbGeAlD
Minocycline—MMP9—female reproductive system—uterine cancer	0.00107	0.00744	CbGeAlD
Minocycline—SLC22A11—female reproductive system—uterine cancer	0.00101	0.00705	CbGeAlD
Minocycline—MMP9—female gonad—uterine cancer	0.00097	0.00677	CbGeAlD
Minocycline—CASP3—lymph node—uterine cancer	0.000936	0.00653	CbGeAlD
Minocycline—ALOX5—female reproductive system—uterine cancer	0.000843	0.00588	CbGeAlD
Minocycline—ALOX5—female gonad—uterine cancer	0.000767	0.00535	CbGeAlD
Minocycline—IL1B—lymph node—uterine cancer	0.000748	0.00522	CbGeAlD
Minocycline—VEGFA—lymph node—uterine cancer	0.000736	0.00513	CbGeAlD
Minocycline—SLC22A8—renal system—uterine cancer	0.000712	0.00497	CbGeAlD
Minocycline—MMP9—lymph node—uterine cancer	0.000623	0.00435	CbGeAlD
Minocycline—ALOX5—lymph node—uterine cancer	0.000493	0.00344	CbGeAlD
Minocycline—CYCS—Levonorgestrel—Progesterone—uterine cancer	0.000346	0.065	CbGdCrCtD
Minocycline—CYCS—Metabolism—CYP11A1—uterine cancer	7.57e-05	0.000417	CbGpPWpGaD
Minocycline—VEGFA—Integrated Breast Cancer Pathway—CTNNB1—uterine cancer	7.54e-05	0.000415	CbGpPWpGaD
Minocycline—MMP9—Extracellular matrix organization—CDH1—uterine cancer	7.52e-05	0.000415	CbGpPWpGaD
Minocycline—VEGFA—VEGFA-VEGFR2 Pathway—KRAS—uterine cancer	7.43e-05	0.00041	CbGpPWpGaD
Minocycline—MMP9—Axon guidance—MET—uterine cancer	7.37e-05	0.000406	CbGpPWpGaD
Minocycline—VEGFA—Integrated Breast Cancer Pathway—PTEN—uterine cancer	7.35e-05	0.000405	CbGpPWpGaD
Minocycline—VEGFA—SIDS Susceptibility Pathways—CTNNB1—uterine cancer	7.34e-05	0.000405	CbGpPWpGaD
Minocycline—CASP3—Signaling by NGF—PTEN—uterine cancer	7.31e-05	0.000403	CbGpPWpGaD
Minocycline—CASP3—BDNF signaling pathway—AKT1—uterine cancer	7.3e-05	0.000402	CbGpPWpGaD
Minocycline—VEGFA—Focal Adhesion—ERBB2—uterine cancer	7.17e-05	0.000395	CbGpPWpGaD
Minocycline—CYCS—Metabolism—AKR1C3—uterine cancer	7.15e-05	0.000394	CbGpPWpGaD
Minocycline—VEGFA—Integrated Pancreatic Cancer Pathway—ERBB2—uterine cancer	7.14e-05	0.000393	CbGpPWpGaD
Minocycline—CASP3—Integrated Pancreatic Cancer Pathway—PIK3CA—uterine cancer	7.13e-05	0.000393	CbGpPWpGaD
Minocycline—CASP1—Innate Immune System—ERBB2—uterine cancer	7.08e-05	0.00039	CbGpPWpGaD
Minocycline—MMP9—Spinal Cord Injury—TP53—uterine cancer	7.04e-05	0.000388	CbGpPWpGaD
Minocycline—CASP1—Cytokine Signaling in Immune system—HRAS—uterine cancer	7.03e-05	0.000388	CbGpPWpGaD
Minocycline—CASP3—Integrated Breast Cancer Pathway—AKT1—uterine cancer	7.03e-05	0.000387	CbGpPWpGaD
Minocycline—VEGFA—Signaling by VEGF—KRAS—uterine cancer	7.02e-05	0.000387	CbGpPWpGaD
Minocycline—VEGFA—Integrated Breast Cancer Pathway—EP300—uterine cancer	7.01e-05	0.000386	CbGpPWpGaD
Minocycline—VEGFA—EPH-Ephrin signaling—HRAS—uterine cancer	7.01e-05	0.000386	CbGpPWpGaD
Minocycline—CASP3—Signaling Pathways—INHBA—uterine cancer	6.96e-05	0.000384	CbGpPWpGaD
Minocycline—IL1B—MAPK Signaling Pathway—TP53—uterine cancer	6.92e-05	0.000381	CbGpPWpGaD
Minocycline—CASP3—Integrated Pancreatic Cancer Pathway—TP53—uterine cancer	6.89e-05	0.00038	CbGpPWpGaD
Minocycline—CASP3—Apoptosis—AKT1—uterine cancer	6.88e-05	0.000379	CbGpPWpGaD
Minocycline—MMP9—Signaling by SCF-KIT—KRAS—uterine cancer	6.87e-05	0.000378	CbGpPWpGaD
Minocycline—VEGFA—VEGFA-VEGFR2 Pathway—PIK3CA—uterine cancer	6.83e-05	0.000376	CbGpPWpGaD
Minocycline—VEGFA—SIDS Susceptibility Pathways—EP300—uterine cancer	6.83e-05	0.000376	CbGpPWpGaD
Minocycline—IL1B—Regulation of toll-like receptor signaling pathway—AKT1—uterine cancer	6.8e-05	0.000375	CbGpPWpGaD
Minocycline—IL1B—Immune System—IRF1—uterine cancer	6.72e-05	0.00037	CbGpPWpGaD
Minocycline—VEGFA—Integrated Pancreatic Cancer Pathway—CDKN1B—uterine cancer	6.61e-05	0.000364	CbGpPWpGaD
Minocycline—CYCS—Cellular responses to stress—TP53—uterine cancer	6.6e-05	0.000364	CbGpPWpGaD
Minocycline—CASP1—Immune System—FGFR2—uterine cancer	6.57e-05	0.000362	CbGpPWpGaD
Minocycline—CASP1—Innate Immune System—CDKN1B—uterine cancer	6.56e-05	0.000362	CbGpPWpGaD
Minocycline—CASP3—Signaling by NGF—NRAS—uterine cancer	6.53e-05	0.00036	CbGpPWpGaD
Minocycline—CASP3—MAPK Signaling Pathway—AKT1—uterine cancer	6.45e-05	0.000356	CbGpPWpGaD
Minocycline—VEGFA—Signaling by VEGF—PIK3CA—uterine cancer	6.45e-05	0.000355	CbGpPWpGaD
Minocycline—MMP9—Developmental Biology—SMAD3—uterine cancer	6.42e-05	0.000354	CbGpPWpGaD
Minocycline—VEGFA—Axon guidance—MET—uterine cancer	6.4e-05	0.000353	CbGpPWpGaD
Minocycline—MMP9—Signaling Pathways—AKR1B10—uterine cancer	6.37e-05	0.000351	CbGpPWpGaD
Minocycline—VEGFA—VEGFA-VEGFR2 Pathway—HRAS—uterine cancer	6.32e-05	0.000348	CbGpPWpGaD
Minocycline—MMP9—Signaling by SCF-KIT—PIK3CA—uterine cancer	6.31e-05	0.000348	CbGpPWpGaD
Minocycline—VEGFA—Focal Adhesion—CTNNB1—uterine cancer	6.27e-05	0.000346	CbGpPWpGaD
Minocycline—CASP3—Signaling Pathways—AKR1C1—uterine cancer	6.27e-05	0.000345	CbGpPWpGaD
Minocycline—VEGFA—Integrated Pancreatic Cancer Pathway—CTNNB1—uterine cancer	6.25e-05	0.000344	CbGpPWpGaD
Minocycline—CASP1—Innate Immune System—CTNNB1—uterine cancer	6.2e-05	0.000342	CbGpPWpGaD
Minocycline—ALOX5—Metabolism—POLD1—uterine cancer	6.12e-05	0.000337	CbGpPWpGaD
Minocycline—VEGFA—Focal Adhesion—PTEN—uterine cancer	6.11e-05	0.000337	CbGpPWpGaD
Minocycline—VEGFA—Integrated Pancreatic Cancer Pathway—PTEN—uterine cancer	6.09e-05	0.000336	CbGpPWpGaD
Minocycline—CASP1—Innate Immune System—PTEN—uterine cancer	6.04e-05	0.000333	CbGpPWpGaD
Minocycline—IL1B—Immune System—FBXW7—uterine cancer	6.02e-05	0.000332	CbGpPWpGaD
Minocycline—IL1B—Cytokine Signaling in Immune system—NRAS—uterine cancer	6.01e-05	0.000331	CbGpPWpGaD
Minocycline—VEGFA—Signaling by VEGF—HRAS—uterine cancer	5.96e-05	0.000329	CbGpPWpGaD
Minocycline—IL1B—MAPK Signaling Pathway—AKT1—uterine cancer	5.84e-05	0.000322	CbGpPWpGaD
Minocycline—MMP9—Signaling by SCF-KIT—HRAS—uterine cancer	5.84e-05	0.000322	CbGpPWpGaD
Minocycline—CASP3—Integrated Pancreatic Cancer Pathway—AKT1—uterine cancer	5.82e-05	0.000321	CbGpPWpGaD
Minocycline—VEGFA—Integrated Pancreatic Cancer Pathway—EP300—uterine cancer	5.81e-05	0.00032	CbGpPWpGaD
Minocycline—VEGFA—Cellular responses to stress—CDKN2A—uterine cancer	5.76e-05	0.000318	CbGpPWpGaD
Minocycline—CASP1—Innate Immune System—EP300—uterine cancer	5.76e-05	0.000318	CbGpPWpGaD
Minocycline—ALOX5—Metabolism—AKR1C1—uterine cancer	5.72e-05	0.000315	CbGpPWpGaD
Minocycline—VEGFA—Integrated Breast Cancer Pathway—KRAS—uterine cancer	5.64e-05	0.000311	CbGpPWpGaD
Minocycline—CASP3—Signaling by NGF—KRAS—uterine cancer	5.62e-05	0.00031	CbGpPWpGaD
Minocycline—VEGFA—VEGFA-VEGFR2 Pathway—AKT1—uterine cancer	5.58e-05	0.000307	CbGpPWpGaD
Minocycline—VEGFA—Developmental Biology—SMAD3—uterine cancer	5.57e-05	0.000307	CbGpPWpGaD
Minocycline—CYCS—Metabolism—STK11—uterine cancer	5.57e-05	0.000307	CbGpPWpGaD
Minocycline—CYCS—Metabolism—CYP19A1—uterine cancer	5.57e-05	0.000307	CbGpPWpGaD
Minocycline—VEGFA—Signaling Pathways—AKR1B10—uterine cancer	5.53e-05	0.000305	CbGpPWpGaD
Minocycline—CASP1—Innate Immune System—NRAS—uterine cancer	5.39e-05	0.000297	CbGpPWpGaD
Minocycline—MMP9—Axon guidance—ERBB2—uterine cancer	5.39e-05	0.000297	CbGpPWpGaD
Minocycline—MMP9—Signaling Pathways—RNF43—uterine cancer	5.28e-05	0.000291	CbGpPWpGaD
Minocycline—VEGFA—Signaling by VEGF—AKT1—uterine cancer	5.27e-05	0.00029	CbGpPWpGaD
Minocycline—MMP9—Developmental Biology—MET—uterine cancer	5.26e-05	0.00029	CbGpPWpGaD
Minocycline—VEGFA—Cellular responses to stress—CXCL8—uterine cancer	5.23e-05	0.000288	CbGpPWpGaD
Minocycline—IL1B—Cytokine Signaling in Immune system—KRAS—uterine cancer	5.17e-05	0.000285	CbGpPWpGaD
Minocycline—CASP3—Signaling by NGF—PIK3CA—uterine cancer	5.16e-05	0.000284	CbGpPWpGaD
Minocycline—MMP9—Signaling by SCF-KIT—AKT1—uterine cancer	5.15e-05	0.000284	CbGpPWpGaD
Minocycline—VEGFA—Cellular responses to stress—CDKN1B—uterine cancer	5.1e-05	0.000281	CbGpPWpGaD
Minocycline—ALOX5—Metabolism—RRM2—uterine cancer	5.1e-05	0.000281	CbGpPWpGaD
Minocycline—VEGFA—Integrated Breast Cancer Pathway—TP53—uterine cancer	5.01e-05	0.000276	CbGpPWpGaD
Minocycline—ALOX5—Metabolism—DCN—uterine cancer	4.95e-05	0.000273	CbGpPWpGaD
Minocycline—IL1B—Immune System—SOCS3—uterine cancer	4.93e-05	0.000272	CbGpPWpGaD
Minocycline—CASP1—Immune System—CDH1—uterine cancer	4.89e-05	0.00027	CbGpPWpGaD
Minocycline—MMP9—Signaling Pathways—INHBA—uterine cancer	4.83e-05	0.000266	CbGpPWpGaD
Minocycline—CASP3—Signaling Pathways—AKR1C3—uterine cancer	4.82e-05	0.000266	CbGpPWpGaD
Minocycline—CASP3—Signaling by NGF—HRAS—uterine cancer	4.77e-05	0.000263	CbGpPWpGaD
Minocycline—IL1B—Cytokine Signaling in Immune system—PIK3CA—uterine cancer	4.75e-05	0.000262	CbGpPWpGaD
Minocycline—CASP3—Signaling Pathways—PGR—uterine cancer	4.7e-05	0.000259	CbGpPWpGaD
Minocycline—VEGFA—Axon guidance—ERBB2—uterine cancer	4.68e-05	0.000258	CbGpPWpGaD
Minocycline—VEGFA—Integrated Pancreatic Cancer Pathway—KRAS—uterine cancer	4.67e-05	0.000258	CbGpPWpGaD
Minocycline—ALOX5—Metabolism—CYP11A1—uterine cancer	4.66e-05	0.000257	CbGpPWpGaD
Minocycline—CASP1—Innate Immune System—KRAS—uterine cancer	4.64e-05	0.000256	CbGpPWpGaD
Minocycline—VEGFA—Signaling Pathways—RNF43—uterine cancer	4.59e-05	0.000253	CbGpPWpGaD
Minocycline—VEGFA—Developmental Biology—MET—uterine cancer	4.57e-05	0.000252	CbGpPWpGaD
Minocycline—CASP3—Signaling Pathways—YWHAE—uterine cancer	4.48e-05	0.000247	CbGpPWpGaD
Minocycline—VEGFA—Cellular responses to stress—EP300—uterine cancer	4.48e-05	0.000247	CbGpPWpGaD
Minocycline—ALOX5—Metabolism—AKR1C3—uterine cancer	4.41e-05	0.000243	CbGpPWpGaD
Minocycline—IL1B—Cytokine Signaling in Immune system—HRAS—uterine cancer	4.4e-05	0.000242	CbGpPWpGaD
Minocycline—MMP9—Signaling Pathways—AKR1C1—uterine cancer	4.35e-05	0.00024	CbGpPWpGaD
Minocycline—VEGFA—Focal Adhesion—PIK3CA—uterine cancer	4.31e-05	0.000238	CbGpPWpGaD
Minocycline—CASP3—Signaling Pathways—FBXW7—uterine cancer	4.3e-05	0.000237	CbGpPWpGaD
Minocycline—VEGFA—Integrated Pancreatic Cancer Pathway—PIK3CA—uterine cancer	4.3e-05	0.000237	CbGpPWpGaD
Minocycline—CASP1—Innate Immune System—PIK3CA—uterine cancer	4.26e-05	0.000235	CbGpPWpGaD
Minocycline—VEGFA—Integrated Breast Cancer Pathway—AKT1—uterine cancer	4.23e-05	0.000233	CbGpPWpGaD
Minocycline—CASP3—Signaling by NGF—AKT1—uterine cancer	4.22e-05	0.000232	CbGpPWpGaD
Minocycline—VEGFA—Signaling Pathways—INHBA—uterine cancer	4.19e-05	0.000231	CbGpPWpGaD
Minocycline—CYCS—Metabolism—MTHFR—uterine cancer	4.19e-05	0.000231	CbGpPWpGaD
Minocycline—VEGFA—Integrated Pancreatic Cancer Pathway—TP53—uterine cancer	4.16e-05	0.000229	CbGpPWpGaD
Minocycline—MMP9—Axon guidance—VEGFA—uterine cancer	4.15e-05	0.000229	CbGpPWpGaD
Minocycline—CASP1—Immune System—ERBB2—uterine cancer	4.13e-05	0.000227	CbGpPWpGaD
Minocycline—IL1B—Immune System—FGFR2—uterine cancer	4.11e-05	0.000226	CbGpPWpGaD
Minocycline—MMP9—Axon guidance—NRAS—uterine cancer	4.1e-05	0.000226	CbGpPWpGaD
Minocycline—VEGFA—Focal Adhesion—HRAS—uterine cancer	3.99e-05	0.00022	CbGpPWpGaD
Minocycline—CASP1—Innate Immune System—HRAS—uterine cancer	3.94e-05	0.000217	CbGpPWpGaD
Minocycline—MMP9—Developmental Biology—ERBB2—uterine cancer	3.85e-05	0.000212	CbGpPWpGaD
Minocycline—VEGFA—Platelet activation, signaling and aggregation—PIK3CA—uterine cancer	3.82e-05	0.000211	CbGpPWpGaD
Minocycline—CASP1—Immune System—CDKN1B—uterine cancer	3.82e-05	0.000211	CbGpPWpGaD
Minocycline—VEGFA—Signaling Pathways—AKR1C1—uterine cancer	3.78e-05	0.000208	CbGpPWpGaD
Minocycline—CASP3—Signaling Pathways—STK11—uterine cancer	3.76e-05	0.000207	CbGpPWpGaD
Minocycline—CASP1—Immune System—CTNNB1—uterine cancer	3.61e-05	0.000199	CbGpPWpGaD
Minocycline—VEGFA—Axon guidance—NRAS—uterine cancer	3.56e-05	0.000196	CbGpPWpGaD
Minocycline—MMP9—Axon guidance—KRAS—uterine cancer	3.53e-05	0.000194	CbGpPWpGaD
Minocycline—VEGFA—Focal Adhesion—AKT1—uterine cancer	3.52e-05	0.000194	CbGpPWpGaD
Minocycline—CASP3—Signaling Pathways—SOCS3—uterine cancer	3.52e-05	0.000194	CbGpPWpGaD
Minocycline—CASP1—Immune System—PTEN—uterine cancer	3.52e-05	0.000194	CbGpPWpGaD
Minocycline—VEGFA—Integrated Pancreatic Cancer Pathway—AKT1—uterine cancer	3.51e-05	0.000193	CbGpPWpGaD
Minocycline—CASP1—Innate Immune System—AKT1—uterine cancer	3.48e-05	0.000192	CbGpPWpGaD
Minocycline—ALOX5—Metabolism—CYP19A1—uterine cancer	3.43e-05	0.000189	CbGpPWpGaD
Minocycline—ALOX5—Metabolism—STK11—uterine cancer	3.43e-05	0.000189	CbGpPWpGaD
Minocycline—CASP3—Signaling Pathways—CDKN2B—uterine cancer	3.37e-05	0.000186	CbGpPWpGaD
Minocycline—MMP9—Developmental Biology—CTNNB1—uterine cancer	3.36e-05	0.000185	CbGpPWpGaD
Minocycline—CASP1—Immune System—EP300—uterine cancer	3.36e-05	0.000185	CbGpPWpGaD
Minocycline—MMP9—Signaling Pathways—AKR1C3—uterine cancer	3.35e-05	0.000185	CbGpPWpGaD
Minocycline—VEGFA—Developmental Biology—ERBB2—uterine cancer	3.34e-05	0.000184	CbGpPWpGaD
Minocycline—CASP3—Signaling Pathways—IGF1R—uterine cancer	3.27e-05	0.00018	CbGpPWpGaD
Minocycline—MMP9—Signaling Pathways—PGR—uterine cancer	3.26e-05	0.00018	CbGpPWpGaD
Minocycline—ALOX5—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	3.22e-05	0.000178	CbGpPWpGaD
Minocycline—VEGFA—Cellular responses to stress—TP53—uterine cancer	3.21e-05	0.000177	CbGpPWpGaD
Minocycline—CASP1—Immune System—NRAS—uterine cancer	3.14e-05	0.000173	CbGpPWpGaD
Minocycline—MMP9—Developmental Biology—EP300—uterine cancer	3.13e-05	0.000172	CbGpPWpGaD
Minocycline—VEGFA—Platelet activation, signaling and aggregation—AKT1—uterine cancer	3.12e-05	0.000172	CbGpPWpGaD
Minocycline—MMP9—Signaling Pathways—YWHAE—uterine cancer	3.11e-05	0.000172	CbGpPWpGaD
Minocycline—CASP3—Signaling Pathways—SMAD3—uterine cancer	3.08e-05	0.00017	CbGpPWpGaD
Minocycline—ALOX5—Metabolism of lipids and lipoproteins—EP300—uterine cancer	3.07e-05	0.000169	CbGpPWpGaD
Minocycline—VEGFA—Axon guidance—KRAS—uterine cancer	3.06e-05	0.000169	CbGpPWpGaD
Minocycline—IL1B—Immune System—CDH1—uterine cancer	3.06e-05	0.000168	CbGpPWpGaD
Minocycline—MMP9—Axon guidance—HRAS—uterine cancer	3e-05	0.000165	CbGpPWpGaD
Minocycline—MMP9—Signaling Pathways—FBXW7—uterine cancer	2.98e-05	0.000164	CbGpPWpGaD
Minocycline—MMP9—Developmental Biology—VEGFA—uterine cancer	2.96e-05	0.000163	CbGpPWpGaD
Minocycline—CASP3—Signaling Pathways—FGFR2—uterine cancer	2.93e-05	0.000162	CbGpPWpGaD
Minocycline—MMP9—Developmental Biology—NRAS—uterine cancer	2.93e-05	0.000161	CbGpPWpGaD
Minocycline—VEGFA—Developmental Biology—CTNNB1—uterine cancer	2.92e-05	0.000161	CbGpPWpGaD
Minocycline—VEGFA—Signaling Pathways—AKR1C3—uterine cancer	2.91e-05	0.00016	CbGpPWpGaD
Minocycline—VEGFA—Signaling Pathways—PGR—uterine cancer	2.83e-05	0.000156	CbGpPWpGaD
Minocycline—VEGFA—Developmental Biology—EP300—uterine cancer	2.71e-05	0.00015	CbGpPWpGaD
Minocycline—VEGFA—Signaling Pathways—YWHAE—uterine cancer	2.7e-05	0.000149	CbGpPWpGaD
Minocycline—CASP1—Immune System—KRAS—uterine cancer	2.7e-05	0.000149	CbGpPWpGaD
Minocycline—VEGFA—Hemostasis—EP300—uterine cancer	2.66e-05	0.000147	CbGpPWpGaD
Minocycline—MMP9—Signaling Pathways—STK11—uterine cancer	2.61e-05	0.000144	CbGpPWpGaD
Minocycline—VEGFA—Axon guidance—HRAS—uterine cancer	2.6e-05	0.000144	CbGpPWpGaD
Minocycline—VEGFA—Signaling Pathways—FBXW7—uterine cancer	2.59e-05	0.000143	CbGpPWpGaD
Minocycline—IL1B—Immune System—ERBB2—uterine cancer	2.58e-05	0.000142	CbGpPWpGaD
Minocycline—ALOX5—Metabolism—MTHFR—uterine cancer	2.58e-05	0.000142	CbGpPWpGaD
Minocycline—VEGFA—Developmental Biology—NRAS—uterine cancer	2.54e-05	0.00014	CbGpPWpGaD
Minocycline—MMP9—Developmental Biology—KRAS—uterine cancer	2.52e-05	0.000139	CbGpPWpGaD
Minocycline—CASP3—Signaling Pathways—ESR1—uterine cancer	2.51e-05	0.000138	CbGpPWpGaD
Minocycline—VEGFA—Hemostasis—NRAS—uterine cancer	2.49e-05	0.000137	CbGpPWpGaD
Minocycline—CASP1—Immune System—PIK3CA—uterine cancer	2.48e-05	0.000137	CbGpPWpGaD
Minocycline—MMP9—Signaling Pathways—SOCS3—uterine cancer	2.44e-05	0.000135	CbGpPWpGaD
Minocycline—IL1B—Immune System—CDKN1B—uterine cancer	2.39e-05	0.000132	CbGpPWpGaD
Minocycline—MMP9—Signaling Pathways—CDKN2B—uterine cancer	2.34e-05	0.000129	CbGpPWpGaD
Minocycline—CYCS—Metabolism—PTEN—uterine cancer	2.33e-05	0.000128	CbGpPWpGaD
Minocycline—CASP1—Immune System—HRAS—uterine cancer	2.3e-05	0.000127	CbGpPWpGaD
Minocycline—ALOX5—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	2.27e-05	0.000125	CbGpPWpGaD
Minocycline—MMP9—Signaling Pathways—IGF1R—uterine cancer	2.27e-05	0.000125	CbGpPWpGaD
Minocycline—VEGFA—Signaling Pathways—STK11—uterine cancer	2.26e-05	0.000125	CbGpPWpGaD
Minocycline—IL1B—Immune System—CTNNB1—uterine cancer	2.26e-05	0.000124	CbGpPWpGaD
Minocycline—CYCS—Metabolism—EP300—uterine cancer	2.22e-05	0.000122	CbGpPWpGaD
Minocycline—CASP3—Signaling Pathways—CCL2—uterine cancer	2.21e-05	0.000122	CbGpPWpGaD
Minocycline—IL1B—Immune System—PTEN—uterine cancer	2.2e-05	0.000121	CbGpPWpGaD
Minocycline—VEGFA—Developmental Biology—KRAS—uterine cancer	2.19e-05	0.00012	CbGpPWpGaD
Minocycline—VEGFA—Hemostasis—KRAS—uterine cancer	2.14e-05	0.000118	CbGpPWpGaD
Minocycline—MMP9—Developmental Biology—HRAS—uterine cancer	2.14e-05	0.000118	CbGpPWpGaD
Minocycline—MMP9—Signaling Pathways—SMAD3—uterine cancer	2.14e-05	0.000118	CbGpPWpGaD
Minocycline—VEGFA—Signaling Pathways—SOCS3—uterine cancer	2.12e-05	0.000117	CbGpPWpGaD
Minocycline—IL1B—Immune System—EP300—uterine cancer	2.1e-05	0.000116	CbGpPWpGaD
Minocycline—MMP9—Signaling Pathways—FGFR2—uterine cancer	2.04e-05	0.000112	CbGpPWpGaD
Minocycline—VEGFA—Signaling Pathways—CDKN2B—uterine cancer	2.03e-05	0.000112	CbGpPWpGaD
Minocycline—CASP1—Immune System—AKT1—uterine cancer	2.03e-05	0.000112	CbGpPWpGaD
Minocycline—VEGFA—Signaling Pathways—IGF1R—uterine cancer	1.97e-05	0.000109	CbGpPWpGaD
Minocycline—VEGFA—Hemostasis—PIK3CA—uterine cancer	1.97e-05	0.000109	CbGpPWpGaD
Minocycline—IL1B—Immune System—NRAS—uterine cancer	1.96e-05	0.000108	CbGpPWpGaD
Minocycline—VEGFA—Hemostasis—TP53—uterine cancer	1.91e-05	0.000105	CbGpPWpGaD
Minocycline—MMP9—Developmental Biology—AKT1—uterine cancer	1.89e-05	0.000104	CbGpPWpGaD
Minocycline—VEGFA—Developmental Biology—HRAS—uterine cancer	1.86e-05	0.000102	CbGpPWpGaD
Minocycline—VEGFA—Signaling Pathways—SMAD3—uterine cancer	1.85e-05	0.000102	CbGpPWpGaD
Minocycline—CASP3—Signaling Pathways—ERBB2—uterine cancer	1.84e-05	0.000102	CbGpPWpGaD
Minocycline—VEGFA—Hemostasis—HRAS—uterine cancer	1.82e-05	0.0001	CbGpPWpGaD
Minocycline—VEGFA—Signaling Pathways—FGFR2—uterine cancer	1.77e-05	9.74e-05	CbGpPWpGaD
Minocycline—CASP3—Signaling Pathways—CXCL8—uterine cancer	1.75e-05	9.63e-05	CbGpPWpGaD
Minocycline—MMP9—Signaling Pathways—ESR1—uterine cancer	1.74e-05	9.6e-05	CbGpPWpGaD
Minocycline—CASP3—Signaling Pathways—CDKN1B—uterine cancer	1.71e-05	9.4e-05	CbGpPWpGaD
Minocycline—IL1B—Immune System—KRAS—uterine cancer	1.69e-05	9.31e-05	CbGpPWpGaD
Minocycline—CYCS—Metabolism—PIK3CA—uterine cancer	1.64e-05	9.05e-05	CbGpPWpGaD
Minocycline—VEGFA—Developmental Biology—AKT1—uterine cancer	1.64e-05	9.04e-05	CbGpPWpGaD
Minocycline—CASP3—Signaling Pathways—CTNNB1—uterine cancer	1.61e-05	8.88e-05	CbGpPWpGaD
Minocycline—VEGFA—Hemostasis—AKT1—uterine cancer	1.61e-05	8.87e-05	CbGpPWpGaD
Minocycline—CASP3—Signaling Pathways—PTEN—uterine cancer	1.57e-05	8.66e-05	CbGpPWpGaD
Minocycline—IL1B—Immune System—PIK3CA—uterine cancer	1.55e-05	8.55e-05	CbGpPWpGaD
Minocycline—MMP9—Signaling Pathways—CCL2—uterine cancer	1.53e-05	8.45e-05	CbGpPWpGaD
Minocycline—VEGFA—Signaling Pathways—ESR1—uterine cancer	1.51e-05	8.34e-05	CbGpPWpGaD
Minocycline—CASP3—Signaling Pathways—EP300—uterine cancer	1.5e-05	8.26e-05	CbGpPWpGaD
Minocycline—IL1B—Immune System—HRAS—uterine cancer	1.44e-05	7.91e-05	CbGpPWpGaD
Minocycline—ALOX5—Metabolism—PTEN—uterine cancer	1.43e-05	7.91e-05	CbGpPWpGaD
Minocycline—CASP3—Signaling Pathways—VEGFA—uterine cancer	1.42e-05	7.82e-05	CbGpPWpGaD
Minocycline—CASP3—Signaling Pathways—NRAS—uterine cancer	1.4e-05	7.72e-05	CbGpPWpGaD
Minocycline—ALOX5—Metabolism—EP300—uterine cancer	1.37e-05	7.54e-05	CbGpPWpGaD
Minocycline—CYCS—Metabolism—AKT1—uterine cancer	1.34e-05	7.4e-05	CbGpPWpGaD
Minocycline—VEGFA—Signaling Pathways—CCL2—uterine cancer	1.33e-05	7.34e-05	CbGpPWpGaD
Minocycline—MMP9—Signaling Pathways—ERBB2—uterine cancer	1.28e-05	7.05e-05	CbGpPWpGaD
Minocycline—IL1B—Immune System—AKT1—uterine cancer	1.27e-05	6.99e-05	CbGpPWpGaD
Minocycline—MMP9—Signaling Pathways—CXCL8—uterine cancer	1.21e-05	6.68e-05	CbGpPWpGaD
Minocycline—CASP3—Signaling Pathways—KRAS—uterine cancer	1.21e-05	6.65e-05	CbGpPWpGaD
Minocycline—MMP9—Signaling Pathways—CDKN1B—uterine cancer	1.18e-05	6.53e-05	CbGpPWpGaD
Minocycline—MMP9—Signaling Pathways—CTNNB1—uterine cancer	1.12e-05	6.17e-05	CbGpPWpGaD
Minocycline—VEGFA—Signaling Pathways—ERBB2—uterine cancer	1.11e-05	6.12e-05	CbGpPWpGaD
Minocycline—CASP3—Signaling Pathways—PIK3CA—uterine cancer	1.11e-05	6.11e-05	CbGpPWpGaD
Minocycline—MMP9—Signaling Pathways—PTEN—uterine cancer	1.09e-05	6.01e-05	CbGpPWpGaD
Minocycline—CASP3—Signaling Pathways—TP53—uterine cancer	1.07e-05	5.91e-05	CbGpPWpGaD
Minocycline—VEGFA—Signaling Pathways—CXCL8—uterine cancer	1.05e-05	5.8e-05	CbGpPWpGaD
Minocycline—MMP9—Signaling Pathways—EP300—uterine cancer	1.04e-05	5.73e-05	CbGpPWpGaD
Minocycline—VEGFA—Signaling Pathways—CDKN1B—uterine cancer	1.03e-05	5.67e-05	CbGpPWpGaD
Minocycline—CASP3—Signaling Pathways—HRAS—uterine cancer	1.03e-05	5.65e-05	CbGpPWpGaD
Minocycline—ALOX5—Metabolism—PIK3CA—uterine cancer	1.01e-05	5.58e-05	CbGpPWpGaD
Minocycline—MMP9—Signaling Pathways—VEGFA—uterine cancer	9.85e-06	5.43e-05	CbGpPWpGaD
Minocycline—MMP9—Signaling Pathways—NRAS—uterine cancer	9.73e-06	5.36e-05	CbGpPWpGaD
Minocycline—VEGFA—Signaling Pathways—CTNNB1—uterine cancer	9.71e-06	5.35e-05	CbGpPWpGaD
Minocycline—VEGFA—Signaling Pathways—PTEN—uterine cancer	9.47e-06	5.22e-05	CbGpPWpGaD
Minocycline—CASP3—Signaling Pathways—AKT1—uterine cancer	9.05e-06	4.99e-05	CbGpPWpGaD
Minocycline—VEGFA—Signaling Pathways—EP300—uterine cancer	9.03e-06	4.98e-05	CbGpPWpGaD
Minocycline—VEGFA—Signaling Pathways—NRAS—uterine cancer	8.45e-06	4.66e-05	CbGpPWpGaD
Minocycline—MMP9—Signaling Pathways—KRAS—uterine cancer	8.37e-06	4.62e-05	CbGpPWpGaD
Minocycline—ALOX5—Metabolism—AKT1—uterine cancer	8.27e-06	4.56e-05	CbGpPWpGaD
Minocycline—MMP9—Signaling Pathways—PIK3CA—uterine cancer	7.69e-06	4.24e-05	CbGpPWpGaD
Minocycline—MMP9—Signaling Pathways—TP53—uterine cancer	7.44e-06	4.1e-05	CbGpPWpGaD
Minocycline—VEGFA—Signaling Pathways—KRAS—uterine cancer	7.27e-06	4.01e-05	CbGpPWpGaD
Minocycline—MMP9—Signaling Pathways—HRAS—uterine cancer	7.12e-06	3.92e-05	CbGpPWpGaD
Minocycline—VEGFA—Signaling Pathways—PIK3CA—uterine cancer	6.68e-06	3.68e-05	CbGpPWpGaD
Minocycline—VEGFA—Signaling Pathways—TP53—uterine cancer	6.46e-06	3.56e-05	CbGpPWpGaD
Minocycline—MMP9—Signaling Pathways—AKT1—uterine cancer	6.29e-06	3.46e-05	CbGpPWpGaD
Minocycline—VEGFA—Signaling Pathways—HRAS—uterine cancer	6.18e-06	3.41e-05	CbGpPWpGaD
Minocycline—VEGFA—Signaling Pathways—AKT1—uterine cancer	5.46e-06	3.01e-05	CbGpPWpGaD
